Inside the $230 billion our new Longevity Biotech Report says the pipeline is already worth – no regulatory rewrite required.

Phil Newman analyzes Oura’s IPO and lawsuit, movement context in dementia, GenFlow dog trial, Rentosertib aging clocks, and ...

Telomir’s oncology compound helped fish with age-related retinal damage see better and moved two aging-linked markers toward ...

Coya Therapeutics hits its 100th ALS trial enrollment and publishes new preclinical data, both pointing to the same ...

Enveda raised $311 million to push its AI-discovered medicines forward, including one aimed at life after GLP-1 drugs.

A new connector lets Function Health members bring lab results and biomarker trends straight into Meta’s personal AI agent, ...

LOY-003, a daily tablet for large and giant breeds, has earned RXE acceptance, the third such milestone for a Loyal lifespan ...

Seoul biotech’s redesigned method makes circular RNA up to seven times more efficient to build, widening what RNA medicine can treat.

Our new Longevity Biotech Report puts a number on longevity's payoff – and asks who actually gets to cash it in.

With one in five citizens now 65 or older, Taiwan’s largest healthy-aging expo argued that older adults are a workforce to ...

Open benchmark tests whether AI can reason across aging biology – and finds specialist models can outperform far larger systems.

Belgian clinical data show Allegro’s nanotech injection Hydrocelin delivers lasting knee osteoarthritis relief from a single ...